Expression of Kit and platelet-derived growth factor receptors α and β in cholangiocarcinoma, and case report of therapy with imatinib mesylate (STI571)

Anti-Cancer Drugs

Volumn 14, Issue 8, 2003, Pages 651-657

  Holcombe, Randall F ^a   Gu, Mai ^b   Imagawa, David ^c   Milovanovic, Tatjana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

c kit; Cholangiocarcinoma; Imatinib mesylate; Tyrosine kinases

Indexed keywords

ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; CA 19-9 ANTIGEN; DIURETIC AGENT; GEMCITABINE; IMATINIB; PIPERAZINE DERIVATIVE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISONE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR; STEROID; TUMOR MARKER;

ABDOMINAL DISEASE; ADULT; ANAMNESIS; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; BIOSYNTHESIS; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER STAGING; CANCER TISSUE; CASE REPORT; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREAM; DIURETIC THERAPY; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG TOLERABILITY; EDEMA; ENTEROPATHY; ERYTHEMA; EYELID EDEMA; FEMALE; GENE EXPRESSION; HAND DISEASE; HUMAN; HUMAN TISSUE; HYPERTENSION; INTRAHEPATIC BILE DUCT; LABORATORY TEST; LIVER DISEASE; LYMPH NODE METASTASIS; METABOLIC DISORDER; METABOLISM; MORBIDITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RECEPTOR UPREGULATION; SAMPLE; STATISTICAL SIGNIFICANCE; STATISTICS; TOPICAL TREATMENT; TREATMENT INDICATION;

ANTINEOPLASTIC AGENTS; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CHOLANGIOCARCINOMA; FEMALE; GENE EXPRESSION; HUMANS; MIDDLE AGED; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR BETA;

EID: 0142124896     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200309000-00011     Document Type: Article

References (29)

1. Ahrendt SA, Nakeeb A, Pitt HA. Cholangiocarcinoma. Clin Liver Dis 2001; 5:191-218.
2. Rumalla A, Petersen BT. Diagnosis and therapy of biliary tract malignancy. Semin Gastrointest Dis 2000; 11:168-163.
3. Ahrendt SA, Rashid A, Chaw JT, Eisenberger CF, Pitt HA, Disransky D. p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer. J Hepatobiliary Pancreat Surg 2000; 7: 426-431.
4. Della Torre G, Pasquini G, Pilotti S, Alasio L, Civelli E, Cozzi G, et al. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas. Diagn Mol Pathol 2000; 9:41-46.
5. Kang YK, Kim WH, Lee HW, Lee HK, Kim YI. Mutation of p53 and K-ras and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest 1999; 79:477-483.
6. Fiorentino M, D'Errico A, Altimari A, Barozzi C, Grigioni WF. High levels of BCL-2 messenger RNA detected by in situ hybridization in human hepatocellular and cholangiocellular carcinomas. Diagn Mol Pathol 1999; 8:189-194.
7. Collier JD, Guo K, Mathew J, May FE, Bennett MK, Corbett IP, et al. C-erbB-2 oncogene expression in hepatocellular carcinoma and cholangiocarcinoma. J Hepatol 1992; 14:377-380.
8. Terada T, Ashida K, Endo K, Horie S, Maeta H, Matsunaga Y, et al. C-erbB-2 protein is expressed in hepatolithiasis and cholangiocarcinoma. Histopathology 1998; 33:325-331.
9. Tsuneyama K, Kono N, Yamashiro M, Kouda W, Sabit A, Sasaki M, et al. Aberrant expression of stem cell factor on biliary epithelial cells and peribiliary infiltration of c-kit-expressing mast cells in hepatolithiasis and primary sclerosing cholangitis: a possible contribution to bile duct fibrosis. J Pathol 1999; 189:609-614.
10. Fujio K, Hu Z, Evarts RP, Marsden ER, Niu CH, Thorgeirsson SS. Coexpression of stem cell factor and c-kit in embryonic and adult liver. Exp Cell Res 1996; 224:243-250.
11. Blakolmer K, Jaskiewicz K, Dunsford HA, Robson SC. Hematopoietic stem cell markers are expressed by ductal plate and bile duct cells in developing human liver. Hepatology 1995; 21:1510-1516.
12. Grappone C, Pinzani M, Parola M, Pellegrini G, Caligiuri A, DeFranco R, et al. Expression of platelet-derived growth factor in newly formed cholangiocytes during experimental biliary fibrosis in rats. J Hepatol 1999; 31:100-109.
13. Su WC, Shiesh SC, Liu HS, Chen CY, Chow NH, Lin XZ. Expression of oncogene products HER2/neu and Ras and fibrosis-related growth factors bFGF, TCP-beta, and PDGF in bile from biliary malignancies and inflammatory disorders. Dig Dis Sci 2001; 46:1387-1392.
14. Mauro MJ, O'Dwyer M, Heinrich MC, Drucker BJ. STI571: a paradigm of new agents for cancer therapeutics. J Clin Oncol 2002; 20:325-334.
15. Drucker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-1037.
16. Drucker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344:1038-1042.
17. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358:1421-1423.
18. Joensuu H, Robers PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344:1052-1056.
19. Demetri GD. Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol 2001; 28:19-26.
20. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CD, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001; 20:5054-5058.
21. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-932.
22. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumors. Ann Med 2001; 33: 451-455.
23. George D. Platelet-derived growth factor receptors: a therapeutic target in solid tumors. Semin Oncol 2001; 28:27-33.
24. Pietras K, Ostman A, Sjoquist M, Buchdunger E, Reed RK, Heldin CH, et al. Inhibition of platelet-derived growth factor receptors reduces interstitial hypergention and increases transcapillary transport in tumors. Cancer Res 2001; 61:2929-2934.
25. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, et al. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997; 90:4947-4952.
26. Tomasson MH, Williams IR, Hasserjian R, Udomsakdi C, McGrath SM, Schwaller J, et al. TEL/PDGFbetaR induces hematologic malignancies in mice that respond to a specific tyrosine kinase inhibitor. Blood 1999; 93:1707-1714.
27. Heinrich MC, Blanke CD, Drucker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20:1692-1703.
28. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000; 156:791-795.
29. Hiirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998; 279:577-580.